1. In a long-term follow-up study of an earlier randomized control trial, participants demonstrated sustained immunity 10 years after receiving a 3-dose series of human papilloma virus (HPV) vaccination. 2. There were no HPV-related malignancies or vaccine-related serious adverse events during the follow-up period. Evidence Rating Level: 1 (Excellent) Study Rundown: The risk of HPV-related